
-
Jasper Therapeutics NasdaqCM:JSPR Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Location: 2200 Bridge Pkwy, Redwood City, CA, 94065, United States | Website: https://jaspertx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
39.12M
Cash
48.8M
Avg Qtr Burn
-17.43M
Short % of Float
17.60%
Insider Ownership
1.27%
Institutional Own.
88.04%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Briquilimab Details Severe combined immunodeficiency due to complete RAG1/2 deficiency | Phase 2 Update | |
Briquilimab (SA SC) Details Asthma | Phase 1/2 Data readout | |
Briquilimab (SC) Details Chronic spontaneous urticaria (CSU) | Phase 1/2 Data readout | |
Briquilimab (SC) Details Cold urticaria (ColdU) or symptomatic dermographism (SD) Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 1/2 Data readout |